We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
(Approval lapsed 31/08/2022) Thiotepa for Injection, USP 15mg/vial (Novadoz)
Section 19A approved medicine
(Approval lapsed 31/08/2022) Thiotepa for Injection, USP 15mg/vial (Novadoz)
Section 19A approval holder
Reach Pharmaceuticals Pty Ltd ABN 25 623 897 183
Phone
0478 061 879
Approved until
Status
Lapsed
Indication(s)
As conditioning treatment prior to haematopoietic progenitor cell transplantation